Immunohistochemistry reveals tumor cell positivity for CD30, CD68, CD163, ALK1, ALK (D5F3), and EMA; Genetic testing shows ALK gene rearrangement in tumor cells but with different ALK fusion partners, mainly SQSTM1 (52%) and VCL (30%). Here, TNFRSF8 is linked to neoplasm.